A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples